Glenmark Life Sciences IPO Subscription Status

Glenmark Life Sciences IPO Subscription Status

Glenmark Life Sciences IPO subscription to start from 27 July 2021 to 29 July 2021. The Initial Public offer of Equity Shares comprising a fresh issue of up to Rs.10,600 million and an offer for sale of up 6,300,000 equity shares. Price range for the offer has been fixed at Rs 695 – 720 per share.

Glenmark Life Sciences IPO Subscription Status Live

DayDateQIBNIIRetailTotal
Day 127-Jul-2021 17:000.00x0.85x5.17x2.78x
Day 228-Jul-2021 17:001.38x3.39x9.28x5.78x
Day 329-Jul-2021 17:0036.96x122.54x14.63x44.17x

About Glenmark Life Sciences

Glenmark Life Science is the leading developer and manufacturer of select high value, non-commoditized active pharmaceutical ingredients (“APIs”) in chronic therapeutic areas, including cardiovascular disease (“CVS”), central nervous system disease (“CNS”), pain management and diabetes.

Glenmark Life Sciences IPO Price – Details

DescriptionGLS IPO Details
Public IssueInitial Public offer of [.] Equity Shares aggregating upto Rs.[.] million comprising a Fresh Issue of up to Rs. 10,600 million and an Offer for Sale of up to 6,300,000 equity shares
Issue Open  Date27-Jul-21
Issue Close Date29-Jul-21
Issue TypeBook Built 
IPO Price Band₹ 695 to ₹ 720 per equity share
Face Value ₹ 2
Market Lot 20 Equity Shares and in multiples thereof
Minimum Order Quantity 20 Equity Shares
Maximum Subscription Amount for Retail InvestorRs. 2,00,000
Listing BSE, NSE
NSE SymbolGLS
IPO Market Timings 10.00 a.m. to 5.00 p.m.

GLS IPO Subscription Status – FAQs

How much Glenmark Life Sciences IPO subscribed on Day 3?

The Glenmark Life Sciences IPO subscribed 44.17 times on day 3

How much Glenmark Life Sciences IPO subscribed on Day 2?

The Glenmark Life Sciences IPO subscribed 5.78 times on day 2.

How much Glenmark Life Sciences IPO retail subscription on Day 1 ?

The Glenmark Life Sciences IPO retail subscription is 2.78 times on day 1

Follow us on Telegram for all latest updates

Related Articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest Articles